The Bio Report

The ability to discover new drugs can be limited by the tools and technologies small companies can access. Alloy Therapeutics says it democratizing access to a set of technologies and capabilities that are foundational for discovering and developing biologics. We spoke to Errik Anderson, CEO of Alloy Therapeutics, discusses the challenges of drug discovery the company is seeking to address, its business model, and the dealmaking it has done to build beyond platform technologies to become involved in the discovery and development of therapeutic candidates.